Not known Details About BRD4 inhibition by ABBV-744 in cancer research studies
In Section C, contributors will get ABBV-744 and oral navitoclax. In Segment D, contributors will obtain ABBV-744 and ruxolitinib. Members will obtain treatment right up until illness progression or even the contributors are not able to tolerate the study drugs.There may be bigger treatment burden for members On this trial in comparison to their co